PTGX
NASDAQ · Biotechnology
Protagonist Therapeutics Inc
$99.36
+0.51 (+0.52%)
Performance
1D
—
1W
—
1M
—
3M
+19.25%
6M
+19.38%
1Y
+131.23%
YTD
+13.97%
Open$98.51
Previous Close$98.85
Day High$100.15
Day Low$97.00
52W High$107.84
52W Low$41.29
Volume—
Avg Volume672.1K
Market Cap6.39B
P/E Ratio—
EPS$-2.04
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$85.10
Above
SMA 200
$67.75
Above
RSI (14)
58.3
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
19 analysts
Price Target
-69.3% upside
Current
$99.36
$99.36
Target
$30.47
$30.47
$24.78
$30.47 avg
$49.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.55M | 38.77M | 743.95M |
| Net Income | -131,658,232 | -98,686,107 | -91,860,800 |
| Profit Margin | -282.8% | -268.7% | -12.4% |
| EBITDA | -158,643,281 | -125,519,377 | -161,541,358 |
| Free Cash Flow | — | — | -86,698,990 |
| Rev Growth | +20.1% | +20.1% | +6.6% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |